Investors in Pfizer Inc. spinout Labrys Biologics Inc.'s $31 million series A round expect the newco's anti-CGRP mAb to be both best- and first-in-class for chronic migraine prophylaxis.

venBio led last week's round, with Canaan Partners, InterWest Partners and Sofinnova Ventures participating.